Ekso Bionics (NASDAQ:EKSO) Earns Buy Rating from HC Wainwright

Ekso Bionics (NASDAQ:EKSO)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $9.00 price target on the stock.

A number of other research analysts also recently weighed in on EKSO. Lake Street Capital cut their price target on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. StockNews.com began coverage on Ekso Bionics in a report on Tuesday. They set a “hold” rating on the stock.

Ekso Bionics Stock Down 9.7 %

NASDAQ:EKSO opened at $0.71 on Tuesday. The company has a market cap of $15.66 million, a price-to-earnings ratio of -1.10 and a beta of 1.47. Ekso Bionics has a 52-week low of $0.50 and a 52-week high of $2.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The stock’s fifty day moving average price is $0.70 and its two-hundred day moving average price is $0.96.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The firm had revenue of $4.13 million for the quarter, compared to the consensus estimate of $6.00 million. During the same period in the prior year, the firm posted ($0.24) earnings per share. On average, analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.